Celgene Corp (CELG)

113.47
NASDAQ : Health Care
Prev Close 113.06
Day Low/High 112.74 / 115.14
52 Wk Low/High 93.05 / 127.00
Avg Volume 4.76M
Exchange NASDAQ
Shares Outstanding 775.20M
Market Cap 87.64B
EPS 2.00
P/E Ratio 42.99
Div & Yield N.A. (N.A)

Latest News

Stocks on Track for Fresh Records as Health Care Sector Climbs

Stocks on Track for Fresh Records as Health Care Sector Climbs

Stocks are on track to close at fresh records on Friday as the health care sector makes a comeback after a bruising week.

Stocks Extend Rally as Health Care Sector Makes Comeback

Stocks Extend Rally as Health Care Sector Makes Comeback

Stocks move higher on Friday, trading at records, as the health care sector makes a comeback after a bruising week.

I'm Buying Biotech on This Trump Scare

I'm Buying Biotech on This Trump Scare

If the market is going to overreact to every new missive from Trump, I plan to take advantage.

Dow Scores Another Record for Third Consecutive Day; S&P 500 Also Hits New High

Dow Scores Another Record for Third Consecutive Day; S&P 500 Also Hits New High

The Dow Jones Industrial Average's winning streak continued after closing higher for the 18th time in 22 sessions. The S&P 500 also hit a new record high.

Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally

Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally

The S&P 500 and Dow Jones Industrial Average trade at session highs early Wednesday afternoon as a broad rally overshadows a slump in health care stocks.

S&P 500 and Dow Reverse Losses to Post Intraday Records

S&P 500 and Dow Reverse Losses to Post Intraday Records

The S&P 500 reverses an earlier loss to post small gains, trading at a new intraday record, thanks to broad gains across all sectors save for health care.

TnAcity Data Presented At SABCS Evaluates The Investigational Use Of ABRAXANE® As First-Line Treatment Of Metastatic Triple Negative Breast Cancer

TnAcity Data Presented At SABCS Evaluates The Investigational Use Of ABRAXANE® As First-Line Treatment Of Metastatic Triple Negative Breast Cancer

Celgene Corporation (NASDAQ:CELG) today announced that the results of its randomized phase II tnAcity trial of ABRAXANE ® for injectable suspension (paclitaxel protein-bound particles for injectable suspension)...

Phase III Studies Present Additional Evidence For REVLIMID® (lenalidomide) As Maintenance Therapy In Multiple Myeloma

Phase III Studies Present Additional Evidence For REVLIMID® (lenalidomide) As Maintenance Therapy In Multiple Myeloma

Celgene Corporation (NASDAQ:CELG), today announced results from two studies (Abstracts #1143, LBA-1) evaluating the investigational use of REVLIMID® (lenalidomide) maintenance therapy in patients with multiple myeloma.

ABOUND Data Presented At The World Conference On Lung Cancer Further Explores Safety And Efficacy Of ABRAXANE® For Challenging Patient Populations

ABOUND Data Presented At The World Conference On Lung Cancer Further Explores Safety And Efficacy Of ABRAXANE® For Challenging Patient Populations

Celgene Corporation (NASDAQ:CELG) today announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE ® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)...

Combined Analysis Of Oral Epigenetic Therapy, CC-486, Demonstrated Hematologic Responses In Patients Who Received Prior Epigenetic Hypo-Methylating Agents (HMA)

Combined Analysis Of Oral Epigenetic Therapy, CC-486, Demonstrated Hematologic Responses In Patients Who Received Prior Epigenetic Hypo-Methylating Agents (HMA)

Abstract #905 -- Celgene Corporation (NASDAQ:CELG), today announced results from an analysis of three phase I/II studies evaluating CC-486 in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia...

Acceleron And Celgene Announce Updated Results From Phase 2 Studies Of Luspatercept In Beta-Thalassemia Presented At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron And Celgene Announce Updated Results From Phase 2 Studies Of Luspatercept In Beta-Thalassemia Presented At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron Pharma Inc. (NASDAQ: XLRN) and Celgene Corporation (NASDAQ: CELG) today announced Phase 2 results from an open-label three-month base study and the ongoing long-term safety extension study with luspatercept in...

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

I spent the weekend with thousands of blood disease researchers. This is what happened.

Acceleron And Celgene Announce Preliminary Results From An Investigator Initiated Phase 2 Study Of Sotatercept In Myelofibrosis At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron And Celgene Announce Preliminary Results From An Investigator Initiated Phase 2 Study Of Sotatercept In Myelofibrosis At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary results from an ongoing investigator initiated Phase 2 study with investigational drug sotatercept in patients with...

Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment

Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment

While a phase III study progresses, Acceleron is searching for different populations of MDS patients where luspatercept might also be effective.

Acceleron And Celgene Announce Updated Results From Ongoing Phase 2 Studies Of Luspatercept In Myelodysplastic Syndromes At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron And Celgene Announce Updated Results From Ongoing Phase 2 Studies Of Luspatercept In Myelodysplastic Syndromes At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary Phase 2 results from the ongoing three-month base and long-term extension studies with investigational drug luspatercept...

Celgene Corporation, Dana-Farber Cancer Institute And University Of Arkansas For Medical Sciences Establish The Myeloma Genome Project

Celgene Corporation, Dana-Farber Cancer Institute And University Of Arkansas For Medical Sciences Establish The Myeloma Genome Project

Celgene Corporation (NASDAQ:CELG), Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences today announced the creation of the Myeloma Genome Project, a collaborative initiative aimed at compiling...

Oil Prices Keep Rising on OPEC Deal; Bluebird, Celgene T-Cell Therapy Sees Success

Oil Prices Keep Rising on OPEC Deal; Bluebird, Celgene T-Cell Therapy Sees Success

Oil prices continued their upward climb Thursday, buoyed by Wednesday's landmark OPEC agreement.

'Mad Money' Lightning Round: Gilead Sciences, Celgene, Express Scripts

'Mad Money' Lightning Round: Gilead Sciences, Celgene, Express Scripts

Jim Cramer says he prefers Celgene to Gilead, and Walgreens Boots Alliance to Express Scripts.

Jim Cramer's 'Mad Money' Recap: Investors See Washington Going Pro-Business

Jim Cramer's 'Mad Money' Recap: Investors See Washington Going Pro-Business

Jim Cramer remains a fan of industrials, transports, banks and domestic oil producers.

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.

Crude Surge Marches Dow to Near Record Close

Crude Surge Marches Dow to Near Record Close

Wall Street was torn in two with the energy sector marching the Dow Jones Industrial Average higher, while health care and tech weighed on the Nasdaq.

Dow Climbs as Crude Rally Lights Fire Under Energy Sector, S&P 500 Falls

Dow Climbs as Crude Rally Lights Fire Under Energy Sector, S&P 500 Falls

The Dow Jones Industrial Average leads markets on Wednesday as a rally in crude oil lights a fire under the energy sector.

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks turn mixed Wednesday as a rally in crude oil fails to provide an across-the-board lift.

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.

Starbucks, Facebook, Apple: Doug Kass' Views

Starbucks, Facebook, Apple: Doug Kass' Views

Doug Kass shares his thoughts on how faster growth won't be easy and how the debt and deficits are out of control.

C, AAPL, FB: Jim Cramer's Views

C, AAPL, FB: Jim Cramer's Views

Cramer shares his views on how much further Citigroup and Goldman Sachs have to run and cautions that you can't wait for everyone to love a stock.

Nearly 350 Abstracts Evaluating Celgene Therapies To Be Presented At American Society Of Hematology Annual Meeting (ASH)

Nearly 350 Abstracts Evaluating Celgene Therapies To Be Presented At American Society Of Hematology Annual Meeting (ASH)

Celgene Corporation (NASDAQ:CELG) today announced that data from nearly 350 abstracts, including more than 150 oral presentations, evaluating Celgene investigational agents and investigational uses of marketed products will...

Cramer: Trump Rally is a FANG + FANG Affair

Cramer: Trump Rally is a FANG + FANG Affair

Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.